OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency

Background: The Phase 3 fliGHt Trial evaluated children with growth hormone deficiency (GHD) of a broad range of baseline demographics and treatment durations who switched from daily growth hormone (hGH; somatropin) therapy to once-weekly TransCon hGH. TransCon hGH is an investigational long-acting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Maniatis, Aristides K, Nadgir, Ulhas, Saenger, Paul, Mick, Gail, Reifschneider, Kent L, Abuzzahab, Mary Jennifer, Deeb, Larry, Fox, Larry A, Woods, Katie A, Peng, Jessica M, Karpf, David B, Shu, Aimee D, Song, Wenjie, Casella, Samuel J, Thornton, Paul S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Pediatric Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209171/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.963
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados